FIRST AMENDMENT TO EXCLUSIVE LICENSE AND COMMERCIALIZATION AGREEMENTExclusive License and Commercialization Agreement • March 27th, 2023 • POINT Biopharma Global Inc. • Pharmaceutical preparations
This First Amendment to the Exclusive License and Commercialization Agreement (this “Amendment”) is dated 04 November 2022 but is deemed to take effect as of December 16, 2020 (“Effective Date”) and is entered into by and between: Point Biopharma Inc., a Delaware corporation with a principal place of business at 511 South Orange Avenue, No. 2093, Newark, New Jersey, 07103, USA (“POINT”); Canadian Molecular Probe Consortium having a place of business at c/o McMaster University, Nuclear Research Building A316, 1280 Main Street West, Hamilton, Ontario, Canada, L8S 4K1, (“CanProbe”); Centre for Probe Development and Commercialization having a place of business at McMaster University, Nuclear Research Building A316, 1280 Main Street West, Hamilton, Ontario, Canada, L8S 4K1, (“CPDC”); and The University Health Network having a business office at 101 College Street, Suite 150, Heritage Building, Ma RS Centre, Toronto, Ontario M5G 1L7 Canada (“UHN”).
PERFORMANCE STOCK UNIT AWARD AGREEMENT UNDER THE POINT BIOPHARMA GLOBAL INC. (Employees)Performance Stock Unit Award Agreement • March 27th, 2023 • POINT Biopharma Global Inc. • Pharmaceutical preparations
Pursuant to the POINT Biopharma Global Inc. 2021 Equity Incentive Plan as amended through the date hereof (the “Plan”), POINT Biopharma Global Inc. (the “Company”) hereby grants an award of the number of performance-vesting Restricted Stock Units (the “Performance Stock Units”) listed above (an “Award”) to the Grantee named above. Each Performance Stock Unit shall relate to one share of Common Stock, par value $0.0001 per share (the “Stock”) of the Company.
